

# Tadeusz Robak

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4029192/publications.pdf>

Version: 2024-02-01

624  
papers

24,307  
citations

16451

64  
h-index

10734

138  
g-index

649  
all docs

649  
docs citations

649  
times ranked

18016  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 213-223.	27.0	1,427
2	Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 2425-2437.	27.0	1,261
3	iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. <i>Blood</i> , 2018, 131, 2745-2760.	1.4	1,069
4	Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. <i>Lancet Oncology</i> , The, 2011, 12, 431-440.	10.7	835
5	Venetoclaxâ€“Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2018, 378, 1107-1120.	27.0	684
6	Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression. <i>Journal of Clinical Oncology</i> , 2007, 25, 3892-3901.	1.6	607
7	Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4485-4491.	1.6	604
8	Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1749-1755.	1.6	541
9	Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2007, 25, 5616-5623.	1.6	533
10	Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). <i>Blood</i> , 2012, 119, 1123-1129.	1.4	520
11	Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1756-1765.	1.6	437
12	Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Leukemia</i> , 2019, 33, 379-389.	7.2	396
13	Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. <i>Blood</i> , 2008, 111, 1094-1100.	1.4	369
14	Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. <i>Blood</i> , 2007, 109, 5143-5150.	1.4	356
15	Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2015, 372, 944-953.	27.0	343
16	Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. <i>Leukemia</i> , 2020, 34, 787-798.	7.2	321
17	Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. <i>Lancet</i> , The, 2015, 385, 1873-1883.	13.7	296
18	Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 1822-1828.	1.6	287

#	ARTICLE	IF	CITATIONS
19	Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3441-3452.	1.6	266
20	First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. <i>Blood</i> , 2008, 111, 5486-5495.	1.4	247
21	Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2017, 18, 297-311.	10.7	219
22	Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2441-2448.	1.6	214
23	Drug resistance in multiple myeloma. <i>Cancer Treatment Reviews</i> , 2018, 70, 199-208.	7.7	200
24	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i> , 2017, 129, 553-560.	1.4	193
25	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2019, 393, 253-264.	13.7	187
26	Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. <i>Leukemia</i> , 2018, 32, 1768-1777.	7.2	184
27	Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. <i>Lancet Haematology</i> , the, 2017, 4, e114-e126.	4.6	181
28	Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2004, 72, 314-321.	2.2	172
29	Skin lesions in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2007, 48, 855-865.	1.3	152
30	Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. <i>Mediators of Inflammation</i> , 1998, 7, 347-353.	3.0	141
31	Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 4042-4054.	1.6	141
32	Purine Nucleoside Analogs as Immunosuppressive and Antineoplastic Agents: Mechanism of Action and Clinical Activity. <i>Current Medicinal Chemistry</i> , 2006, 13, 3165-3189.	2.4	138
33	Current and emerging therapies for acute myeloid leukemia. <i>Clinical Therapeutics</i> , 2009, 31, 2349-2370.	2.5	129
34	A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. <i>Blood</i> , 2009, 114, 1166-1173.	1.4	129
35	Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. <i>Blood</i> , 2014, 123, 4136-4142.	1.4	125
36	Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-CSF) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. <i>European Journal of Haematology</i> , 2008, 80, 115-126.	2.2	122

#	ARTICLE	IF	CITATIONS
37	Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). <i>Blood</i> , 2006, 108, 473-479.	1.4	119
38	A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. <i>American Journal of Hematology</i> , 2015, 90, 42-49.	4.1	116
39	Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. <i>Blood</i> , 2017, 129, 2612-2615.	1.4	111
40	Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. <i>Haematologica</i> , 2018, 103, 1502-1510.	3.5	111
41	Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2018, 29, 1266-1272.	1.2	106
42	Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. <i>American Journal of Hematology</i> , 2018, 93, 1301-1310.	4.1	98
43	Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later. <i>Drugs in R and D</i> , 2019, 19, 73-92.	2.2	98
44	New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies. <i>BioDrugs</i> , 2011, 25, 13-25.	4.6	96
45	Hairy-cell leukemia variant: Recent view on diagnosis, biology and treatment. <i>Cancer Treatment Reviews</i> , 2011, 37, 3-10.	7.7	95
46	Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2018, 19, 1449-1458.	10.7	93
47	Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. <i>Blood Advances</i> , 2022, 6, 3440-3450.	5.2	91
48	Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. <i>Blood Advances</i> , 2019, 3, 1799-1807.	5.2	90
49	Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study). <i>Journal of Clinical Oncology</i> , 2010, 28, 1863-1869.	1.6	86
50	High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. <i>Blood</i> , 2018, 132, 892-902.	1.4	83
51	The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumorigenesis and targeted antitumour therapy. <i>Cellular and Molecular Biology Letters</i> , 2005, 10, 479-98.	7.0	80
52	Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. <i>Blood</i> , 2002, 100, 3037-3040.	1.4	78
53	Monoclonal antibodies in the treatment of autoimmune cytopenias. <i>European Journal of Haematology</i> , 2004, 72, 79-88.	2.2	78
54	Older and new purine nucleoside analogs for patients with acute leukemias. <i>Cancer Treatment Reviews</i> , 2013, 39, 851-861.	7.7	78

#	ARTICLE	IF	CITATIONS
55	Cladribine with or without prednisone in the treatment of previously treated and untreated Bâ€cell chronic lymphocytic leukaemia â€” updated results of the multicentre study of 378 patients. <i>British Journal of Haematology</i> , 2000, 108, 357-368.	2.5	77
56	Inhibitors of Apoptosis Proteins (IAPs) as Potential Molecular Targets for Therapy of Hematological Malignancies. <i>Current Molecular Medicine</i> , 2011, 11, 633-649.	1.3	76
57	Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 1031-1043.	10.7	76
58	Safety and Tolerability of Antibody-Drug Conjugates in Cancer. <i>Drug Safety</i> , 2019, 42, 295-314.	3.2	75
59	Current treatment options in hairy cell leukemia and hairy cell leukemia variant. <i>Cancer Treatment Reviews</i> , 2006, 32, 365-376.	7.7	74
60	2â€Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7â€year experience in Poland. <i>European Journal of Haematology</i> , 1999, 62, 49-56.	2.2	73
61	Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 921-947.	4.1	72
62	Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. <i>Blood</i> , 2007, 109, 3672-3675.	1.4	70
63	Purine Nucleoside Analogues in the Treatment of Myeloid Leukemias. <i>Leukemia and Lymphoma</i> , 2003, 44, 391-409.	1.3	69
64	Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. <i>Cancer</i> , 2008, 112, 1529-1537.	4.1	68
65	Effect of Intracoronary Injection of Mononuclear Bone Marrow Stem Cells on Left Ventricular Function in Patients With Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2009, 104, 1336-1342.	1.6	67
66	Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. <i>Leukemia</i> , 2019, 33, 2762-2766.	7.2	67
67	Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases. <i>Molecules</i> , 2009, 14, 1183-1226.	3.8	66
68	Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities. , 2022, 1, .		66
69	2-Chlorodeoxyadenosine (2-CdA) in 2-Hour Versus 24-Hour Intravenous Infusion in the Treatment of Patients with Hairy Cell Leukemia. <i>Leukemia and Lymphoma</i> , 1996, 22, 107-111.	1.3	65
70	Population Pharmacokinetics of Rituximab in Patients With Chronic Lymphocytic Leukemia. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1918-1926.	2.0	65
71	Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. <i>Blood</i> , 2018, 131, 2331-2334.	1.4	64
72	Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion. <i>Haematologica</i> , 2021, 106, 2354-2363.	3.5	62

#	ARTICLE	IF	CITATIONS
73	Targeted Drugs in Chronic Myeloid Leukemia. <i>Current Medicinal Chemistry</i> , 2008, 15, 3036-3051.	2.4	60
74	Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia. <i>Blood Advances</i> , 2020, 4, 4136-4146.	5.2	60
75	Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia. <i>European Journal of Cancer</i> , 2010, 46, 800-810.	2.8	59
76	Plasmablastic Transformation of Low-grade B-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2013, 37, 272-281.	3.7	59
77	Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus. <i>Mediators of Inflammation</i> , 2003, 12, 293-298.	3.0	58
78	Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. <i>Cellular and Molecular Biology Letters</i> , 2009, 14, 248-72.	7.0	58
79	Expression of Toll-Like Receptors 3, 7, and 9 in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus. <i>Mediators of Inflammation</i> , 2014, 2014, 1-11.	3.0	56
80	Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. <i>Blood</i> , 2012, 120, 3670-3676.	1.4	55
81	Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. <i>Blood</i> , 2022, 140, 839-850.	1.4	55
82	Combination Regimen of Cladribine (2-Chlorodeoxyadenosine), Cytarabine and G-CSF (CLAG) as Induction Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 2000, 39, 121-129.	1.3	54
83	The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant. <i>Bone Marrow Transplantation</i> , 2007, 40, 983-988.	2.4	54
84	Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 352-355.	1.4	54
85	Effect of FCGR2A and FCGR3A variants on CLL outcome. <i>Blood</i> , 2010, 116, 4212-4222.	1.4	54
86	Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. <i>European Cytokine Network</i> , 2006, 17, 60-6.	2.0	53
87	Monoclonal Antibodies in the Treatment of Chronic Lymphoid Leukemias. <i>Leukemia and Lymphoma</i> , 2004, 45, 205-219.	1.3	52
88	Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. <i>Blood</i> , 2009, 114, 4027-4033.	1.4	52
89	GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. <i>Current Opinion in Investigational Drugs</i> , 2009, 10, 588-96.	2.3	52
90	Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. <i>Journal of Hematology and Oncology</i> , 2021, 14, 35.	17.0	51

#	ARTICLE	IF	CITATIONS
91	Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. <i>Cancer</i> , 2006, 107, 1542-1550.	4.1	50
92	Second Malignancies and Richter's Syndrome in Patients with Chronic Lymphocytic Leukemia. <i>Hematology</i> , 2004, 9, 387-400.	1.5	49
93	Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. <i>Haematologica</i> , 2012, 97, 784-791.	3.5	49
94	Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911). <i>Blood</i> , 2013, 122, 528-528.	1.4	49
95	Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2007, 79, 107-113.	2.2	48
96	Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy. <i>Leukemia and Lymphoma</i> , 2015, 56, 1949-1958.	1.3	48
97	Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. <i>Leukemia and Lymphoma</i> , 2017, 58, 1084-1093.	1.3	48
98	Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma. <i>British Journal of Haematology</i> , 1999, 105, 412-419.	2.5	47
99	Circulating endothelial cells in patients with acute myeloid leukemia. <i>European Journal of Haematology</i> , 2005, 75, 492-497.	2.2	47
100	Cladribine in the Treatment of Chronic Lymphocytic Leukemia. <i>Leukemia and Lymphoma</i> , 2001, 40, 551-564.	1.3	46
101	Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients. <i>Annals of Oncology</i> , 2004, 15, 1222-1230.	1.2	46
102	Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. <i>Leukemia and Lymphoma</i> , 2005, 46, 87-100.	1.3	46
103	The discovery and development of romidepsin for the treatment of T-cell lymphoma. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1-15.	5.0	45
104	Lymphocytes T $\beta$ 1 $\gamma$ in clinically normal skin and peripheral blood of patients with systemic lupus erythematosus and their correlation with disease activity. <i>Mediators of Inflammation</i> , 2001, 10, 179-189.	3.0	44
105	Autoimmune haemolytic anaemia in patients with chronic lymphocytic eukaemia treated with 2 $\beta$ -chlorodeoxyadenosine (cladribine). <i>European Journal of Haematology</i> , 1997, 58, 109-113.	2.2	43
106	BCR Signaling in Chronic Lymphocytic Leukemia and Related Inhibitors Currently in Clinical Studies. <i>International Reviews of Immunology</i> , 2013, 32, 358-376.	3.3	42
107	Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. <i>Cancer</i> , 2016, 122, 2050-2056.	4.1	40
108	Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. <i>The Hematology Journal</i> , 2002, 3, 244-250.	1.4	40

#	ARTICLE	IF	CITATIONS
109	Merkel cell carcinoma in a patient with B-cell chronic lymphocytic leukemia treated with cladribine and rituximab. <i>Leukemia and Lymphoma</i> , 2005, 46, 909-914.	1.3	39
110	Current and Emerging Treatments for Chronic Lymphocytic Leukaemia. <i>Drugs</i> , 2009, 69, 2415-2449.	10.9	39
111	2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger. <i>Leukemia</i> , 1999, 13, 518-523.	7.2	38
112	In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells. <i>European Journal of Haematology</i> , 2005, 74, 407-417.	2.2	38
113	Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on Outcome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 44-49.	0.4	38
114	Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial. <i>Blood</i> , 2008, 112, 1ba-1-lba-1.	1.4	38
115	Circulating Total and Active Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinases-1 in Patients with Systemic Lupus Erythematousus. <i>Mediators of Inflammation</i> , 2006, 2006, 1-7.	3.0	37
116	Plasma TNF- $\alpha$ and IL-10 Level-Based Prognostic Model Predicts Outcome of Patients with Diffuse Large B-Cell Lymphoma in Different Risk Groups Defined by the International Prognostic Index. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2010, 58, 131-141.	2.3	37
117	Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1 study. <i>British Journal of Haematology</i> , 2010, 150, 58-71.	2.5	37
118	Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin. <i>Leukemia and Lymphoma</i> , 2013, 54, 284-289.	1.3	36
119	Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2017, 176, 618-628.	2.5	36
120	Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 234-234.	1.4	36
121	A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF-04449913) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 99-99.	1.4	36
122	Hairy cell leukemia variant treated with 2-Chlorodeoxyadenosine—a report of three cases. <i>Leukemia and Lymphoma</i> , 1997, 25, 381-385.	1.3	35
123	Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. <i>Leukemia</i> , 2001, 15, 1510-1516.	7.2	35
124	The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions. <i>Cancers</i> , 2022, 14, 771.	3.7	35
125	TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. <i>Current Opinion in Investigational Drugs</i> , 2009, 10, 1383-90.	2.3	35
126	Forodesine (BCX-1777, Immucillin H) - A New Purine Nucleoside Analogue: Mechanism of Action and Potential Clinical Application. <i>Mini-Reviews in Medicinal Chemistry</i> , 2007, 7, 976-983.	2.4	34



#	ARTICLE	IF	CITATIONS
127	Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment. <i>Leukemia and Lymphoma</i> , 2015, 56, 2309-2314.	1.3	34
128	Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG). <i>Leukemia and Lymphoma</i> , 2017, 58, 2485-2488.	1.3	34
129	Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma. <i>Leukemia Research</i> , 2009, 33, 332-335.	0.8	33
130	Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG). <i>International Journal of Infectious Diseases</i> , 2010, 14, e132-e140.	3.3	33
131	Purine Nucleoside Analogs in the Treatment of Rarer Chronic Lymphoid Leukemias. <i>Current Pharmaceutical Design</i> , 2012, 18, 3373-3388.	1.9	33
132	Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients. <i>Blood</i> , 2013, 121, 3650-3657.	1.4	33
133	Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders. <i>Current Opinion in Molecular Therapeutics</i> , 2008, 10, 294-309.	2.8	33
134	The Search for Optimal Treatment in Relapsed and Refractory Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 2002, 43, 281-291.	1.3	32
135	Recent progress in the management of chronic lymphocytic leukemia. <i>Cancer Treatment Reviews</i> , 2007, 33, 710-728.	7.7	32
136	Novel Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia. <i>Current Cancer Drug Targets</i> , 2008, 8, 156-171.	1.6	32
137	<i>CD38</i> Gene Polymorphisms Contribute to Genetic Susceptibility to B-Cell Chronic Lymphocytic Leukemia: Evidence from Two Case-Control Studies in Polish Caucasians. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 945-953.	2.5	32
138	Monoclonal Antibodies in the Treatment of Systemic Lupus Erythematosus. <i>Current Drug Targets</i> , 2009, 10, 26-37.	2.1	32
139	New nucleoside analogs for patients with hematological malignancies. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 343-359.	4.1	32
140	The Influence of Maltotriose-Modified Poly(propylene imine) Dendrimers on the Chronic Lymphocytic Leukemia Cells <i>in Vitro</i> : Dense Shell G4 PPI. <i>Molecular Pharmaceutics</i> , 2013, 10, 2490-2501.	4.6	32
141	Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 803-813.e7.	0.4	32
142	2-Chlorodeoxyadenosine (Cladribine) in the Treatment of Elderly Patients with B-Cell Chronic Lymphocytic Leukemia. <i>Leukemia and Lymphoma</i> , 1999, 34, 151-156.	1.3	31
143	G-CSF Administered in Time-sequenced Setting During Remission Induction and Consolidation Therapy of Adult Acute Lymphoblastic Leukemia has Beneficial Influence on Early Recovery and Possibly Improves Long-term Outcome: A Randomized Multicenter Study. <i>Leukemia and Lymphoma</i> , 2002, 43, 315-325.	1.3	31
144	Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1249-1265.	4.1	31

#	ARTICLE	IF	CITATIONS
145	Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial. <i>Blood</i> , 2008, 112, 328-328.	1.4	31
146	Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia. <i>European Cytokine Network</i> , 2003, 14, 149-53.	2.0	31
147	Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies. <i>European Journal of Haematology</i> , 2001, 66, 188-194.	2.2	30
148	Alemtuzumab in the Treatment of Chronic Lymphocytic Leukemia. <i>BioDrugs</i> , 2005, 19, 9-22.	4.6	30
149	Alemtuzumab for B-cell chronic lymphocytic leukemia. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1033-1051.	2.4	30
150	A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2014, 167, 466-477.	2.5	30
151	Rituximab Followed by Cladribine in the Treatment of Heavily Pretreated Patients with Indolent Lymphoid Malignancies. <i>Leukemia and Lymphoma</i> , 2004, 45, 937-944.	1.3	29
152	The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2008, 49, 1452-1462.	1.3	29
153	Impact of intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction on left ventricular perfusion and function: a 6-month follow-up gated 99mTc-MIBI single-photon emission computed tomography study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 587-593.	6.4	29
154	Polymorphisms of TNF and IL10 genes and clinical outcome of patients with chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 287-296.	2.8	28
155	Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. <i>Leukemia and Lymphoma</i> , 2018, 59, 880-887.	1.3	28
156	Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 92.	17.0	28
157	Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. <i>Leukemia</i> , 2021, 35, 1864-1872.	7.2	28
158	The distribution of peripheral blood dendritic cells assayed by a new panel of anti-BDCA monoclonal antibodies in healthy representatives of the polish population. <i>Cellular and Molecular Biology Letters</i> , 2004, 9, 497-509.	7.0	28
159	Therapy of Chronic Lymphocytic Leukaemia with Purine Nucleoside Analogues. <i>Drugs and Aging</i> , 2005, 22, 983-1012.	2.7	27
160	Depsipeptide (FK228) as a Novel Histone Deacetylase Inhibitor: Mechanism of Action and Anticancer Activity. <i>Mini-Reviews in Medicinal Chemistry</i> , 2007, 7, 1062-1069.	2.4	27
161	Toll-Like Receptors and their Role in Hematologic Malignancies. <i>Current Molecular Medicine</i> , 2009, 9, 324-335.	1.3	27
162	Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers. <i>International Journal of Hematology</i> , 2010, 91, 792-798.	1.6	27

#	ARTICLE	IF	CITATIONS
163	Anti-CD37 antibodies for chronic lymphocytic leukemia. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 651-661.	3.1	27
164	Venetoclax in the treatment of chronic lymphocytic leukemia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 353-366.	3.3	27
165	Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. <i>American Journal of Hematology</i> , 2019, 94, 554-562.	4.1	27
166	Clinical significance of circulating dendritic cells in patients with systemic lupus erythematosus. <i>Mediators of Inflammation</i> , 2004, 13, 171-180.	3.0	26
167	Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells. <i>Leukemia Research</i> , 2006, 30, 1521-1529.	0.8	26
168	Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion. <i>Cancer</i> , 2009, 115, 94-100.	4.1	26
169	Influence of high expression of Smac/DIABLO protein on the clinical outcome in acute myeloid leukemia patients. <i>Leukemia Research</i> , 2010, 34, 1308-1313.	0.8	26
170	Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia. <i>Future Oncology</i> , 2013, 9, 69-91.	2.4	26
171	Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial). <i>Leukemia</i> , 2017, 31, 1240-1243.	7.2	26
172	Novel and Emerging Drugs for Acute Myeloid Leukemia: Pharmacology and Therapeutic Activity. <i>Current Medicinal Chemistry</i> , 2011, 18, 638-666.	2.4	25
173	Polymorphism of CD44 Influences the Efficacy of CD34+ Cells Mobilization in Patients with Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 986-991.	2.0	25
174	Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia. <i>Seminars in Oncology</i> , 2016, 43, 280-290.	2.2	25
175	Front-line treatment of CLL in the era of novel agents. <i>Cancer Treatment Reviews</i> , 2017, 53, 70-78.	7.7	25
176	Circulating proangiogenic molecules PIGF, SDF-1 and sVCAM-1 in patients with systemic lupus erythematosus. <i>European Cytokine Network</i> , 2007, 18, 181-7.	2.0	25
177	Activity of 2-chlorodeoxyadenosine (cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 1997, 26, 99-105.	1.3	24
178	Combination Regimen of 2-Chlorodeoxyadenosine (Cladribine), Mitoxantrone and Dexamethasone (CMD) in the Treatment of Refractory and Recurrent Low Grade Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 1999, 32, 359-363.	1.3	24
179	Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy. <i>Bone Marrow Transplantation</i> , 2004, 33, 1225-1229.	2.4	24
180	Peripheral blood lymphocyte apoptosis and circulating dendritic cells in patients with systemic lupus erythematosus: correlation with immunological status and disease-related symptoms. <i>Clinical Rheumatology</i> , 2006, 25, 225-233.	2.2	24

#	ARTICLE	IF	CITATIONS
181	Kinetics and apoptotic profile of circulating endothelial cells as prognostic factors for induction treatment failure in newly diagnosed acute myeloid leukemia patients. <i>Annals of Hematology</i> , 2008, 87, 97-106.	1.8	24
182	Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam <sup>®</sup> 10%) in patients with immune thrombocytopenia. <i>Hematology</i> , 2010, 15, 351-359.	1.5	24
183	Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial. <i>American Journal of Hematology</i> , 2017, 92, 359-366.	4.1	24
184	Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. <i>American Journal of Hematology</i> , 2018, 93, 1402-1410.	4.1	24
185	Circulating vascular endothelial growth factor (VEGF) and its soluble receptors in patients with chronic lymphocytic leukemia. <i>European Cytokine Network</i> , 2005, 16, 41-6.	2.0	24
186	Current treatment options in prolymphocytic leukemia. <i>Medical Science Monitor</i> , 2007, 13, RA69-80.	1.1	24
187	Serum Levels of IL-6 Type Cytokines and Soluble IL-6 Receptors in Active B-Cell Chronic Lymphocytic Leukemia and in Cladribine Induced Remission. <i>Mediators of Inflammation</i> , 1999, 8, 277-286.	3.0	23
188	No Influence of 3435C>T ABCB1 (MDR1) Gene Polymorphism on Risk of Adult Acute Myeloid Leukemia and P-glycoprotein Expression in Blast Cells. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 707-711.	2.0	23
189	Interaction of doxorubicin and idarubicin with red blood cells from acute myeloid leukaemia patients. <i>Cell Biology International</i> , 2006, 30, 127-132.	3.0	23
190	Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinoside cytarabine. <i>Anti-Cancer Drugs</i> , 2009, 20, 693-701.	1.4	23
191	Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial. <i>Blood</i> , 2019, 134, 499-499.	1.4	23
192	Novel Purine Nucleoside Analogues for Hematological Malignancies. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2008, 3, 123-136.	1.6	23
193	Bruton's Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives. <i>Journal of Clinical Medicine</i> , 2022, 11, 2807.	2.4	23
194	The Role of Nucleoside Analogues in the Treatment of Chronic Lymphocytic Leukemia-Lessons Learned from Prospective Randomized Trials. <i>Leukemia and Lymphoma</i> , 2002, 43, 537-548.	1.3	22
195	Caspase-mediated Cell Death in Hematological Malignancies: Theoretical Considerations, Methods of Assessment, and Clinical Implications. <i>Leukemia and Lymphoma</i> , 2003, 44, 1089-1104.	1.3	22
196	Hodgkin's Type of Richter's Syndrome in Familial Chronic Lymphocytic Leukemia Treated with Cladribine and Cyclophosphamide. <i>Leukemia and Lymphoma</i> , 2003, 44, 859-866.	1.3	22
197	Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients. <i>Cancer</i> , 2008, 113, 367-375.	4.1	22
198	SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2021, 138, 396-396.	1.4	22

#	ARTICLE	IF	CITATIONS
199	Distribution of allelic variants of functional C3435T polymorphism of drug transporter MDR1 gene in a sample of Polish population. <i>Polish Journal of Pharmacology</i> , 2002, 54, 495-500.	0.3	22
200	Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia. <i>Mediators of Inflammation</i> , 2003, 12, 167-171.	3.0	21
201	Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies. <i>Transfusion and Apheresis Science</i> , 2005, 32, 33-44.	1.0	21
202	Clofarabine as a Novel Nucleoside Analogue Approved to Treat Patients with Haematological Malignancies: Mechanism of Action and Clinical Activity. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009, 9, 805-812.	2.4	21
203	Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes and Myeloid Leukemia. <i>Current Cancer Drug Targets</i> , 2011, 11, 837-848.	1.6	21
204	Rituximab for chronic lymphocytic leukemia. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 503-515.	3.1	21
205	Intragenic Variations in BTLA Gene Influence mRNA Expression of BTLA Gene in Chronic Lymphocytic Leukemia Patients and Confer Susceptibility to Chronic Lymphocytic Leukemia. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2016, 64, 137-145.	2.3	21
206	Autoimmune thrombocytopenia: Current treatment options in adults with a focus on novel drugs. <i>European Journal of Haematology</i> , 2019, 103, 531-541.	2.2	21
207	The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients. <i>Cancers</i> , 2020, 12, 2569.	3.7	21
208	VEGF, ANGPT1, ANGPT2, and MMP-9 expression in the autologous hematopoietic stem cell transplantation and its impact on the time to engraftment. <i>Annals of Hematology</i> , 2017, 96, 2103-2112.	1.8	21
209	Circulating angiogenic cytokines in multiple myeloma and related disorders. <i>European Cytokine Network</i> , 2003, 14, 40-51.	2.0	21
210	Circulating TCR $\beta$ <sup>+</sup> Cells in the Patients with Systemic Lupus Erythematosus. <i>Mediators of Inflammation</i> , 1999, 8, 305-312.	3.0	20
211	Richter's Syndrome Following Cladribine Therapy for Chronic Lymphocytic Leukemia First Manifested as Pathologic Fracture of the Femur. <i>Leukemia and Lymphoma</i> , 2001, 42, 789-796.	1.3	20
212	Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 62-67.	1.3	20
213	Management of hairy cell leukemia variant. <i>Leukemia and Lymphoma</i> , 2011, 52, 53-56.	1.3	20
214	Poor prognosis of <i>H</i> variant of <i>R</i> ichter transformation in chronic lymphocytic leukemia treated with cladribine. <i>British Journal of Haematology</i> , 2012, 158, 286-288.	2.5	20
215	Clonal evolution in <i>CLL</i> patients as detected by <i>FISH</i> versus chromosome banding analysis, and its clinical significance. <i>European Journal of Haematology</i> , 2014, 92, 91-101.	2.2	20
216	Emerging antibody-drug conjugates for treating lymphoid malignancies. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 259-273.	2.4	20

#	ARTICLE	IF	CITATIONS
217	Moxetumomab pasudotox for the treatment of hairy cell leukemia. Expert Opinion on Biological Therapy, 2019, 19, 501-508.	3.1	20
218	First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study. Blood, 2021, 138, 70-70.	1.4	20
219	Râ€oscovitin (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspaseâ€dependent apoptosis. Journal of Cellular Biochemistry, 2010, 109, 217-235.	2.6	19
220	Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia. Expert Review of Anticancer Therapy, 2010, 10, 1529-1543.	2.4	19
221	Common genetic variation at 15q25.2 impacts on chronic lymphocytic leukaemia risk. British Journal of Haematology, 2011, 154, 229-233.	2.5	19
222	Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies. Expert Opinion on Investigational Drugs, 2018, 27, 171-177.	4.1	19
223	Efficacy and Safety of Zanubrutinib in Patients with Treatment-NaÃve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial. Blood, 2020, 136, 11-12.	1.4	19
224	Zanubrutinib in Combination with Venetoclax for Patients with Treatment-NaÃve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Early Results from Arm D of the SEQUOIA (BGB-3111-304) Trial. Blood, 2021, 138, 67-67.	1.4	19
225	Effect of granulocyte-macrophage colony stimulating factor and granulocyte colony stimulating factor on melatonin secretion in rats In vivo and in vitro studies. Journal of Neuroimmunology, 1995, 56, 187-190.	2.3	18
226	Cytokines serum levels as the markers of thyroid activation in Graves' disease. Immunology Letters, 1998, 60, 143-148.	2.5	18
227	High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group. Bone Marrow Transplantation, 2002, 30, 29-34.	2.4	18
228	The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors <i>in vitro</i>. European Journal of Haematology, 2004, 73, 418-426.	2.2	18
229	Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura. Vox Sanguinis, 2011, 101, 138-146.	1.5	18
230	Human leukocyte antigenâ€G polymorphisms influence the clinical outcome in diffuse large <sc>B</sc>â€cell lymphoma. Genes Chromosomes and Cancer, 2015, 54, 185-193.	2.8	18
231	In vitro antileukemic activity of novel adenosine derivatives bearing boron cluster modification. Bioorganic and Medicinal Chemistry, 2016, 24, 5076-5087.	3.0	18
232	Chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) â€ a systematic review and meta-analysis of randomized trials. Leukemia and Lymphoma, 2016, 57, 2047-2057.	1.3	18
233	Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib. Mediators of Inflammation, 2020, 2020, 1-13.	3.0	18
234	Pro-Apoptotic Activity of Honokiol Analogues in B-Cell Lymphoid Malignancies. Blood, 2011, 118, 1663-1663.	1.4	18

#	ARTICLE	IF	CITATIONS
235	Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro. <i>European Journal of Haematology</i> , 2002, 68, 370-375.	2.2	17
236	Chromosomal aberrations in chronic lymphocytic leukemia detected by conventional cytogenetics with DSP30 as a single agent: Comparison with FISH. <i>Leukemia Research</i> , 2011, 35, 1032-1038.	0.8	17
237	Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 911-924.	4.1	17
238	Prognostic value of inhibitor of apoptosis protein family expression in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2529-2535.	1.3	17
239	Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2847-2854.	1.3	17
240	A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis. <i>Blood</i> , 2019, 134, 4078-4078.	1.4	17
241	Lymphoplasmacytic lymphoma with monoclonal gammopathy-related pseudo-Gaucher cell infiltration in bone marrow and spleen—diagnostic and therapeutic dilemmas. <i>Leukemia and Lymphoma</i> , 2002, 43, 2343-50.	1.3	17
242	In vitro sensitivity of B-cell chronic lymphocytic leukemia to cladribine and its combinations with mafosfamide and/or mitoxantrone. <i>Oncology Reports</i> , 2006, 16, 1389-95.	2.6	17
243	PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives. <i>Cancers</i> , 2022, 14, 1571.	3.7	17
244	MONOCLONAL ANTIBODIES REACTING WITH MYELOID CELLS. <i>British Journal of Haematology</i> , 1985, 61, 1-9.	2.5	16
245	Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and JAK2 V617F mutational status. <i>Leukemia and Lymphoma</i> , 2010, 51, 1-7.	1.3	16
246	The differences in thermal profiles between normal and leukemic cells exposed to anticancer drug evaluated by differential scanning calorimetry. <i>Journal of Thermal Analysis and Calorimetry</i> , 2014, 118, 1339-1344.	3.6	16
247	Glasdegib in the treatment of acute myeloid leukemia. <i>Future Oncology</i> , 2019, 15, 3219-3232.	2.4	16
248	Skin changes in hairy cell leukemia. <i>Annals of Hematology</i> , 2021, 100, 615-625.	1.8	16
249	Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 355-355.	1.4	16
250	Idelalisib Plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a Phase 3 Randomized Double-Blind Placebo-Controlled Study. <i>Blood</i> , 2015, 126, LBA-5-LBA-5.	1.4	16
251	Recent Clinical Trials of Cladribine in Hematological Malignancies and Autoimmune Disorders. <i>Reviews on Recent Clinical Trials</i> , 2006, 1, 15-34.	0.8	15
252	Chlorodeoxyadenosine (cladribine)-related eosinophilia in patients with lymphoproliferative diseases. <i>European Journal of Haematology</i> , 1997, 59, 216-220.	2.2	15

#	ARTICLE	IF	CITATIONS
253	Serum Tumor Necrosis Factor- $\beta$ and Interleukin-10 Levels as Markers to Predict Outcome of Patients with Chronic Lymphocytic Leukemia in Different Risk Groups Defined by the IGHV Mutation Status. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2012, 60, 477-486.	2.3	15
254	Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art. <i>Expert Review of Hematology</i> , 2014, 7, 841-857.	2.2	15
255	Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. <i>Haematologica</i> , 2015, 100, e311-4.	3.5	15
256	Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study. <i>Leukemia and Lymphoma</i> , 2018, 59, 896-903.	1.3	15
257	Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the <sc>DACO</sc> trial. <i>American Journal of Hematology</i> , 2018, 93, E125-E127.	4.1	15
258	Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. <i>Nature Communications</i> , 2021, 12, 5395.	12.8	15
259	Efficacy of Subsequent Novel Targeted Therapies, Including Repeated Venetoclax-Rituximab (VenR), in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Previously Treated with Fixed-Duration Venr in the Murano Study. <i>Blood</i> , 2020, 136, 44-45.	1.4	15
260	Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy. <i>Blood</i> , 2022, 140, 285-289.	1.4	15
261	Additive Action of Gemcitabine (2-Deoxy-2-Fluorodeoxycytidine) and 2-Chlorodeoxyadenosine on Murine Leukemias L1210 and P388. <i>Cancer Investigation</i> , 1999, 17, 95-101.	1.3	14
262	High activity of rituximab combined with cladribine and cyclophosphamide in a patient with pulmonary lymphomatoid granulomatosis and bone marrow involvement. <i>Leukemia and Lymphoma</i> , 2006, 47, 1667-1669.	1.3	14
263	Improving FCR immunochemotherapy in CLL. <i>Blood</i> , 2010, 115, 437-438.	1.4	14
264	New Purine Nucleoside Analogs for Acute Lymphoblastic Leukemia. <i>Clinical Cancer Drugs</i> , 2013, 1, 2-10.	0.3	14
265	PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 124, 420-425.	1.4	14
266	Long-Term Follow-up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma. <i>Blood</i> , 2018, 132, 2876-2876.	1.4	14
267	Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment. <i>European Journal of Haematology</i> , 2002, 69, 27-36.	2.2	13
268	An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma. <i>British Journal of Cancer</i> , 2004, 91, 1873-1879.	6.4	13
269	Richter's Syndrome in the Brain First Manifested as an Ischaemic Stroke. <i>Leukemia and Lymphoma</i> , 2004, 45, 1261-1267.	1.3	13
270	Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells. <i>Leukemia and Lymphoma</i> , 2006, 47, 2625-2634.	1.3	13



#	ARTICLE	IF	CITATIONS
271	Novel Drugs for Chronic Lymphoid Leukemias: Mechanism of Action and Therapeutic Activity. <i>Current Medicinal Chemistry</i> , 2009, 16, 2212-2234.	2.4	13
272	Characterization of haematological parameters with bortezomibâ€“melphalanâ€“prednisone <i>versus</i> melphalanâ€“prednisone in newly diagnosed myeloma, with evaluation of longâ€“term outcomes and risk of thromboembolic events with use of erythropoiesisâ€“stimulating agents: analysis of the VISTA trial. <i>British Journal of Haematology</i> , 2011, 153, 212-221.	2.5	13
273	Cytotoxic activity of the amphibian ribonucleases onconase and r-amphinase on tumor cells from B cell lymphoproliferative disorders. <i>International Journal of Oncology</i> , 2014, 45, 419-425.	3.3	13
274	Mantle cell lymphoma: therapeutic options in transplant-ineligible patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 2622-2634.	1.3	13
275	The Expression of the SLITâ€“ROBO Family in Adult Patients with Acute Myeloid Leukemia. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2019, 67, 109-123.	2.3	13
276	Current Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs. <i>Acta Haematologica</i> , 2021, 144, 365-379.	1.4	13
277	Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox. <i>Journal of Clinical Medicine</i> , 2021, 10, 2800.	2.4	13
278	The Comparison of 2-Chlorodeoxyadenosine (2-Cd A) in Combination with Interferon Î± (IFN Î±) or Interferon Î² (IFN Î²) on Granulocyte-Macrophage Progenitor Cells (CFU-GM) and Clonogenic Blasts in (CFU-L) In Vitro Cultures. <i>Leukemia and Lymphoma</i> , 1996, 21, 161-168.	1.3	12
279	Tumour necrosis factor Î± (TNF-Î±), interleukin-6 (IL-6) and their soluble receptors (sTNF-Î±-Rp55 and sIL-6R) serum levels in systemic lupus erythematoses. <i>Mediators of Inflammation</i> , 1996, 5, 435-441.	3.0	12
280	Interaction of anthracyclines with human erythrocytes at hyperthermic temperature. <i>International Journal of Pharmaceutics</i> , 1996, 135, 167-176.	5.2	12
281	Aggressive Primary Plasma Cell Leukemia with Skin Manifestations, Trisomy 8 and Molecular Oligoclonal Features. <i>Leukemia and Lymphoma</i> , 2002, 43, 1067-1073.	1.3	12
282	Human leukocyte antigens HLA DRB1 influence clinical outcome of chronic lymphocytic leukemia. <i>Haematologica</i> , 2007, 92, 710-711.	3.5	12
283	Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 1455-1468.	3.3	12
284	Effects of Toll-like receptor 7 and Toll-like receptor 9 signaling stimulators and inhibitors on chronic lymphocytic leukemia cells ex vivo and their interactions with cladribine. <i>Leukemia and Lymphoma</i> , 2013, 54, 1268-1278.	1.3	12
285	Cladribine in the treatment of acute myeloid leukemia. <i>Leukemia Research</i> , 2014, 38, 425-427.	0.8	12
286	Ofatumumab for treating chronic lymphocytic leukemia: a safety profile. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1945-1959.	2.4	12
287	Jagged-1: a new promising factor associated with favorable prognosis in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 401-406.	1.3	12
288	HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2016, 64, 225-240.	2.3	12

#	ARTICLE	IF	CITATIONS
289	Donor age and C1orf132/MIR29B2C determine age-related methylation signature of blood after allogeneic hematopoietic stem cell transplantation. <i>Clinical Epigenetics</i> , 2016, 8, 93.	4.1	12
290	Bone lesions in hairy cell leukemia: Diagnosis and treatment. <i>European Journal of Haematology</i> , 2020, 105, 682-691.	2.2	12
291	Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles. <i>Blood</i> , 2019, 134, 2591-2591.	1.4	12
292	Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATE™ Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2014, 124, 4696-4696.	1.4	12
293	Results of a phase III randomized, controlled study evaluating the efficacy and safety of idelalisib (IDELA) in combination with ofatumumab (OFA) for previously treated chronic lymphocytic leukemia (CLL). <i>Journal of Clinical Oncology</i> , 2015, 33, 7023-7023.	1.6	12
294	An Open Label, Multi Center Study on the Efficacy and Safety of a Liquid, Ready-to-Use Intravenously Administered Anti-D Immunoglobulin in Patients with Chronic Immune Thrombocytopenic Purpura. <i>Blood</i> , 2004, 104, 3943-3943.	1.4	12
295	Coexistence of Chronic Lymphocytic Leukemia and Essential Thrombocythemia. <i>Leukemia and Lymphoma</i> , 2003, 44, 1425-1431.	1.3	11
296	Exposure to Low Doses of Solar-Simulated Radiation Induces an Increase in the Myeloid Subtype of Blood Dendritic Cells. <i>Scandinavian Journal of Immunology</i> , 2004, 60, 429-435.	2.7	11
297	Primary cutaneous marginal zone B-cell lymphoma in a patient with chronic lymphocytic leukaemia. <i>British Journal of Dermatology</i> , 2007, 157, 591-595.	1.5	11
298	Roscovitine Triggers Apoptosis in B-Cell Chronic Lymphocytic Leukemia Cells with Similar Efficiency as Combinations of Conventional Purine Analogs with Cyclophosphamide. <i>Annals of the New York Academy of Sciences</i> , 2009, 1171, 124-131.	3.8	11
299	Calorimetric study as a potential test for choosing treatment of B-cell chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2009, 33, 308-314.	0.8	11
300	Bortezomib in the treatment of mantle cell lymphoma. <i>Future Oncology</i> , 2015, 11, 2807-2818.	2.4	11
301	Blockage of Wnt/β-Catenin Signaling by Nanoparticles Reduces Survival and Proliferation of CLL Cells In Vitro—Preliminary Study. <i>Macromolecular Bioscience</i> , 2017, 17, 1700130.	4.1	11
302	Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL. <i>Leukemia and Lymphoma</i> , 2017, 58, 1598-1606.	1.3	11
303	Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials. <i>Leukemia and Lymphoma</i> , 2018, 59, 1084-1094.	1.3	11
304	Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study. <i>Leukemia and Lymphoma</i> , 2019, 60, 172-179.	1.3	11
305	Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic lymphocytic leukemia cells. <i>Postępy Higieny i Medycyny Doswiadczalnej</i> , 2013, 67, 107-118.	0.1	11
306	In vitro cytotoxicity of ranpirnase (onconase) in combination with components of R-CHOP regimen against diffuse large B cell lymphoma (DLBCL) cell line. <i>Postępy Higieny i Medycyny Doswiadczalnej</i> , 2013, 67, 1166-1172.	0.1	11

#	ARTICLE	IF	CITATIONS
307	Efficacy and toxicity of low-dose melphalan in myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia. <i>Neoplasma</i> , 2003, 50, 172-5.	1.6	11
308	The interaction of 2-chlorodeoxy adenosine (2-CDA) and interferon $\hat{\pm}$ (IFN- $\hat{\pm}$ ) on normal and myeloid leukemia hematopoiesis in vitro. <i>Leukemia Research</i> , 1994, 18, 275-281.	0.8	10
309	The Influence of Imatinib Mesylate (STI571) used alone or in Combination with Purine Nucleoside Analogues on the Normal and Chronic Myelogenous Leukaemia Progenitor Cells<i>In Vitro</i>. <i>Leukemia and Lymphoma</i> , 2003, 44, 1549-1555.	1.3	10
310	Older and New Formulations of Cladribine. Pharmacology and Clinical Efficacy in Hematological Malignancies. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2006, 1, 23-38.	1.6	10
311	New agents in chronic lymphocytic leukemia. <i>Current Treatment Options in Oncology</i> , 2006, 7, 200-212.	3.0	10
312	Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 1092-1101.	1.3	10
313	Do polymorphisms in ABC transporter genes influence risk of childhood acute lymphoblastic leukemia?. <i>Leukemia Research</i> , 2008, 32, 1173-1175.	0.8	10
314	The Effect of Repeated Exposures to Low-Dose UV Radiation on the Apoptosis of Peripheral Blood Mononuclear Cells. <i>Archives of Dermatology</i> , 2009, 145, 133-8.	1.4	10
315	The emerging therapeutic role of antibody mixtures. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 953-958.	3.1	10
316	Maintenance in CLL. <i>Blood</i> , 2013, 122, 3854-3855.	1.4	10
317	Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies. <i>European Journal of Cancer</i> , 2014, 50, 2677-2684.	2.8	10
318	Potential breakthroughs with investigational drugs for hairy cell leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1419-1431.	4.1	10
319	Clinical relevance of vascular endothelial growth factor type A (VEGFA) and VEGF receptor type 2 (VEGFR2) gene polymorphism in chronic lymphocytic leukemia. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 54, 139-143.	1.4	10
320	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytoowych na rok 2016. <i>Acta Haematologica Polonica</i> , 2016, 47, 39-85.	0.3	10
321	Ibrutinib in chronic lymphocytic leukaemia: alone or in combination?. <i>Lancet Oncology</i> , The, 2016, 17, 129-131.	10.7	10
322	mi<scp>RNA</scp>â€15a, mi<scp>RNA</scp>â€16, mi<scp>RNA</scp>â€126, mi<scp>RNA</scp>â€146a, and mi<scp>RNA</scp>â€223 expressions in autologous hematopoietic stem cell transplantation and their impact on engraftment. <i>European Journal of Haematology</i> , 2018, 100, 426-435.	2.2	10
323	Idelalisib immune-related toxicity is associated with improved treatment response. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-6.	1.3	10
324	The international Prognostic Index for patients with CLL (CLL-IPI): An international meta-analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7002-7002.	1.6	10

#	ARTICLE	IF	CITATIONS
325	Outcomes with ibrutinib by line of therapy in patients with CLL: Analyses from phase III data.. Journal of Clinical Oncology, 2016, 34, 7520-7520.	1.6	10
326	Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS: BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up.. Journal of Clinical Oncology, 2020, 38, 7509-7509.	1.6	10
327	Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1). Medical Science Monitor, 2005, 11, PI71-9.	1.1	10
328	Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia. Leukemia and Lymphoma, 1996, 22, 509-14.	1.3	10
329	Influence of granulocyte-macrophage colony stimulating factor on pituitary-adrenal axis (PAA) in rats in vivo. Pituitary, 1999, 2, 211-216.	2.9	9
330	Influence of gemcitabine (2â€²,2â€²-difluoro-deoxycytidine) and 2-chlorodeoxyadenosine on growth of normal and leukemic cells in vitro. European Journal of Haematology, 2000, 65, 317-321.	2.2	9
331	Does Intensive Treatment with High Dose Chlorambucil and Prednisone as First Line and Cladribine as Second Line Influence the Survival of the Patients with Chronic Lymphocytic Leukemia?. Leukemia and Lymphoma, 2001, 41, 545-557.	1.3	9
332	Langerhans Cell Histiocytosis in a Patient with Systemic Lupus Erythematosus: A Clonal Disease Responding to Treatment with Cladribine, and Cyclophosphamide. Leukemia and Lymphoma, 2002, 43, 2041-2046.	1.3	9
333	2-Chlorodeoxyadenosine alone and in combination with cyclophosphamide and mitoxantrone induce apoptosis in B chronic lymphocytic leukemia cells in vivo. Cancer Detection and Prevention, 2004, 28, 433-442.	2.1	9
334	In vitro sensitivity of B-cell chronic lymphocytic leukemia to cladribine and its combinations with mafosfamide and/or mitoxantrone. Oncology Reports, 2006, 16, 1389.	2.6	9
335	The kinetics and apoptotic profile of circulating endothelial cells in autologous hematopoietic stem cell transplantation in patients with lymphoproliferative disorders. Annals of Hematology, 2013, 92, 1255-1262.	1.8	9
336	Cereblon expression predicts clinical response in chronic lymphocytic leukemia treated with a thalidomide/fludarabine regimen. Leukemia and Lymphoma, 2015, 56, 808-810.	1.3	9
337	Emerging immunological drugs for chronic lymphocytic leukemia. Expert Opinion on Emerging Drugs, 2015, 20, 423-447.	2.4	9
338	Treatment of elderly patients with acute myeloid leukemia adjusted for performance status and presence of comorbidities: a Polish Adult Leukemia Group study. Leukemia and Lymphoma, 2015, 56, 2331-2338.	1.3	9
339	Treatment options for mantle cell lymphoma. Expert Opinion on Pharmacotherapy, 2015, 16, 2497-2507.	1.8	9
340	MGMT promoter methylation as a potential prognostic marker for acute leukemia. Archives of Medical Science, 2017, 6, 1433-1441.	0.9	9
341	A fiveâ€year followâ€up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial. British Journal of Haematology, 2020, 190, 736-740.	2.5	9
342	The management of hematologic malignancies during the COVID-19 pandemic. Expert Opinion on Pharmacotherapy, 2021, 22, 565-582.	1.8	9

#	ARTICLE	IF	CITATIONS
343	The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib. <i>Cancers</i> , 2021, 13, 951.	3.7	9
344	Randomized Multicenter Trial of Cladribine Alone (C) or in Combination with Cyclophosphamide (CC), and COP in Previously Untreated Low Grade B-Cell Non-Hodgkin Lymphoma Patients: The First Interim Analysis.. <i>Blood</i> , 2004, 104, 3305-3305.	1.4	9
345	A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma. <i>Blood</i> , 2010, 116, 312-312.	1.4	9
346	Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 921-921.	1.4	9
347	Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients (pts) ineligible for bone marrow transplantation (BMT).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8500-8500.	1.6	9
348	The effect of subsequent therapies in patients with chronic lymphocytic leukemia previously treated with prednisone and either cladribine or chlorambucil. <i>Haematologica</i> , 2005, 90, 994-6.	3.5	9
349	Antigenic characteristics of circulating CFU-GM in chronic granulocytic leukaemia resemble those of CFU-GM in normal marrow and differ from those in normal blood. <i>Leukemia Research</i> , 1985, 9, 1023-1029.	0.8	8
350	Pituitaryâ€œadrenocortical responses to the chronic administration of granulocyte colony-stimulating factor in rats. <i>Journal of Neuroimmunology</i> , 2000, 102, 73-78.	2.3	8
351	Influence of 2-chlorodeoxyadenosine (cladribine) on human erythrocytes. <i>International Journal of Biochemistry and Cell Biology</i> , 2004, 36, 1645-1654.	2.8	8
352	Changes in leukemic cell nuclei revealed by differential scanning calorimetry. <i>Leukemia and Lymphoma</i> , 2005, 46, 121-128.	1.3	8
353	Elevated plasma levels of the angiogenic tetrapeptide acetyl-ser-asp-lys-pro are found in some patients with hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2009, 50, 2096-2097.	1.3	8
354	The influence of low-dose aspirin and hydroxyurea on plateletâ€œleukocyte interactions in patients with essential thrombocythemia. <i>Blood Coagulation and Fibrinolysis</i> , 2009, 20, 646-651.	1.0	8
355	Spontaneous<i>in vitro</i> apoptosis of<i>de novo</i> chronic lymphocytic leukemia cells correlates with risk of the disease progression. , 2014, 86, 410-417.		8
356	Gene expression of INPP5F as an independent prognostic marker in fludarabine-based therapy of chronic lymphocytic leukemia. <i>Blood Cancer Journal</i> , 2015, 5, e353-e353.	6.2	8
357	Concomitance of monosomal karyotype with at least 5 chromosomal abnormalities is associated with dismal treatment outcome of AML patients with complex karyotype â€œ retrospective analysis of Polish Adult Leukemia Group (PALG). <i>Leukemia and Lymphoma</i> , 2017, 58, 889-897.	1.3	8
358	Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study. <i>Anticancer Research</i> , 2020, 40, 4059-4066.	1.1	8
359	MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 184-184.	1.4	8
360	Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial. <i>Blood</i> , 2019, 134, 2808-2808.	1.4	8

#	ARTICLE	IF	CITATIONS
361	Clinically Significant Responses Achieved with Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B, International, Multicenter, Registration Study. <i>Blood</i> , 2008, 112, 263-263.	1.4	8
362	The impact of agonists and antagonists of TLR3 and TLR9 on concentrations of IL-6, IL10 and sIL-2R in culture supernatants of peripheral blood mononuclear cells derived from patients with systemic lupus erythematosus. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2017, 71, 0-0.	0.1	8
363	Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial. <i>Leukemia and Lymphoma</i> , 2022, 63, 304-314.	1.3	8
364	Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. <i>Leukemia and Lymphoma</i> , 2022, 63, 1375-1386.	1.3	8
365	Antigenic determinants on myeloid leukaemia colony-forming cells resemble those of normal myeloid progenitor cells and differ from those of circulating blast cells. <i>British Journal of Haematology</i> , 1986, 64, 133-148.	2.5	7
366	Different prognosis of acute myeloid leukemia harboring monosomal karyotype with total or partial monosomies determined by FISH: Retrospective PALG study. <i>Leukemia Research</i> , 2013, 37, 293-299.	0.8	7
367	Promising anti-leukemic activity of atorvastatin. <i>Oncology Reports</i> , 2013, 29, 2065-2071.	2.6	7
368	The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma. <i>Expert Opinion on Drug Discovery</i> , 2015, 10, 791-808.	5.0	7
369	Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates. <i>BioDrugs</i> , 2016, 30, 87-93.	4.6	7
370	Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG vs CLL4 (<sc>ML</sc>21283) trial. <i>European Journal of Haematology</i> , 2018, 100, 465-474.	2.2	7
371	Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib. <i>Leukemia</i> , 2020, 34, 3404-3407.	7.2	7
372	Preliminary Safety and Efficacy Report of a Randomized Trial of Alemtuzumab vs Chlorambucil as Front-Line Therapy in 297 Patients with Progressive B-Cell Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2004, 104, 2505-2505.	1.4	7
373	Alemtuzumab (CAMPATH®, MABCAMPATH®) Has Superior Progression Free Survival (PFS) vs Chlorambucil as Front-Line Therapy for Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (BCLL).. <i>Blood</i> , 2006, 108, 301-301.	1.4	7
374	Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab.. <i>Blood</i> , 2009, 114, 3433-3433.	1.4	7
375	Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia.. <i>Blood</i> , 2009, 114, 888-888.	1.4	7
376	Phase IIa Study of Single-Agent MOR208 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Blood</i> , 2015, 126, 1528-1528.	1.4	7
377	Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2016, 128, 4383-4383.	1.4	7
378	Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study. <i>Blood</i> , 2016, 128, 623-623.	1.4	7

#	ARTICLE	IF	CITATIONS
379	Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. Expert Review of Hematology, 2022, 15, 183-194.	2.2	7
380	A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia. Blood Advances, 2022, 6, 4224-4227.	5.2	7
381	Fulminant 2-Chlorodeoxyadenosine-Related Peripheral Neuropathy in a Patient with Paraneoplastic Neurological Syndrome Associated with Lymphoma. Leukemia and Lymphoma, 1996, 21, 343-346.	1.3	6
382	Low-Grade Non-Hodgkin's Lymphoma in a Patient with Systemic Lupus Erythematosus. Leukemia and Lymphoma, 2001, 41, 659-667.	1.3	6
383	The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland. Annals of Hematology, 2005, 84, 63-70.	1.8	6
384	Prognostic value of the bone marrow microvessel density in progressive B-cell chronic lymphocytic leukemia. Leukemia and Lymphoma, 2010, 51, 1351-1353.	1.3	6
385	Toward personalized therapy for chronic lymphocytic leukemia. Cancer Biology and Therapy, 2013, 14, 6-12.	3.4	6
386	New horizons in the treatment of chronic lymphocytic leukemia. Acta Haematologica Polonica, 2014, 45, 122-131.	0.3	6
387	Spontaneous in vitro apoptosis of de novo chronic lymphocytic leukemia cells correlates with risk of the disease progression. , 2014, , n/a-n/a.		6
388	New mutation in hairy cell leukemia. Blood, 2015, 126, 930-931.	1.4	6
389	Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia. International Journal of Oncology, 2015, 46, 1259-1267.	3.3	6
390	Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1371-1391.	3.3	6
391	Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study. Haematologica, 2017, 102, 895-902.	3.5	6
392	The distribution and potential prognostic value of SMAD protein expression in chronic lymphocytic leukemia. Tumor Biology, 2017, 39, 101042831769455.	1.8	6
393	Polymorphism in IKZF1 gene affects clinical outcome in diffuse large B-cell lymphoma. International Journal of Hematology, 2017, 106, 794-800.	1.6	6
394	Distinct Activities of Glycolytic Enzymes Identify Chronic Lymphocytic Leukemia Patients with a more Aggressive Course and Resistance to Chemo-Immunotherapy. EBioMedicine, 2018, 32, 125-133.	6.1	6
395	Minimizing and managing treatment-associated complications in patients with chronic lymphocytic leukemia. Expert Review of Hematology, 2020, 13, 39-53.	2.2	6
396	Investigational treatments for chronic lymphocytic leukemia: a focus on phase 1 and 2 clinical trials. Expert Opinion on Investigational Drugs, 2020, 29, 709-722.	4.1	6

#	ARTICLE	IF	CITATIONS
397	Advances in the pharmacotherapeutic options for primary nodal peripheral T-cell lymphoma. Expert Opinion on Pharmacotherapy, 2021, 22, 1203-1215.	1.8	6
398	The Influence of Imatinib Mesylate (STI571) used alone or in Combination with Purine Nucleoside Analogues on the Normal and Chronic Myelogenous Leukaemia Progenitor Cells In Vitro. Leukemia and Lymphoma, 2003, 44, 1549-1555.	1.3	6
399	Cladribine in Weekly Versus Daily Schedule for Untreated Active Hairy Cell Leukemia: Final Report of Polish Adult Leukemia Group (PALG) Prospective, Randomized, Multicenter Trial.. Blood, 2006, 108, 2485-2485.	1.4	6
400	Romidepsin (depsipeptide) Induces Clinically Significant Responses in Treatment-Refractory CTCL: An International, Multicenter Study.. Blood, 2007, 110, 123-123.	1.4	6
401	The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure.. Blood, 2007, 110, 410-410.	1.4	6
402	A Phase 1 Study of Moxetumomab Pasudotox, An Anti-CD22 Recombinant Immunotoxin, In Relapsed/Refractory Hairy Cell Leukemia (HCL): Updated Results. Blood, 2010, 116, 2516-2516.	1.4	6
403	Decitabine Improves Response Rate and Prolongs Progression Free Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Monosomal Karyotype: A Subgroup Analysis of the Daco-16 Trial. Blood, 2015, 126, 1336-1336.	1.4	6
404	Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study. Blood, 2021, 138, 3793-3793.	1.4	6
405	Influence of cladribine alone and in combinaton with cyclophosphamide or cyclophosphamide and mitoxantrone on bone marrow angiogenesis in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2007, 48, 1042-1044.	1.3	5
406	Detection of P53 mutations in different cancer types is improved by cDNA sequencing. Oncology Letters, 2010, 1, 717-721.	1.8	5
407	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego na rok 2012. Acta Haematologica Polonica, 2012, 43, 7-47.	0.3	5
408	Apoptotic gene expression under influence of fludarabine and cladribine in chronic lymphocytic leukemia-microarray study. Pharmacological Reports, 2012, 64, 412-420.	3.3	5
409	Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2014, 55, 606-610.	1.3	5
410	Pro-Apoptotic Activity of New Honokiol/Triphenylmethane Analogues in B-Cell Lymphoid Malignancies. Molecules, 2016, 21, 995.	3.8	5
411	Personalized therapy tests for the monitoring of chronic lymphocytic leukemia development. Oncology Letters, 2017, 13, 2079-2084.	1.8	5
412	Survival adjusting for crossover: phase 3 study of ibrutinib vs chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica, 2018, 103, e249-e251.	3.5	5
413	Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial. Health and Quality of Life Outcomes, 2019, 17, 173.	2.4	5
414	A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Haematologica, 2020, 105, e164-e168.	3.5	5



#	ARTICLE	IF	CITATIONS
415	The up-to-date role of biologics for the treatment of chronic lymphocytic leukemia. Expert Opinion on Biological Therapy, 2020, 20, 799-812.	3.1	5
416	MicroRNA in Multiple Myeloma - A Role in Pathogenesis and Prognostic Significance. Current Medicinal Chemistry, 2021, 28, 6753-6772.	2.4	5
417	Hairy cell leukemia: a brief update on current knowledge and treatment prospects. Current Opinion in Oncology, 2021, 33, 412-419.	2.4	5
418	Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL). Blood, 2018, 132, 4144-4144.	1.4	5
419	Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia. Blood, 2019, 134, 897-897.	1.4	5
420	Improved Progression-Free Survival (PFS) of Alemtuzumab (Campath®) Plus Fludarabine (Fludara®) Versus Fludarabine Alone as Second-Line Treatment of Patients with B-Cell Chronic Lymphocytic Leukemia: Preliminary Results From a Phase III Randomized Trial.. Blood, 2009, 114, 537-537.	1.4	5
421	Nanoparticles – a Novel Approach to Chronic Lymphocytic Leukemia Treatment?. Blood, 2012, 120, 4601-4601.	1.4	5
422	Phase 2 Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIR™ Protein, In Combination With Bendamustine Vs Bendamustine Alone In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL). Blood, 2013, 122, 2860-2860.	1.4	5
423	Efficacy and Safety of Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in a Subset of Newly Diagnosed Mantle Cell Lymphoma (MCL) Patients (Pts) Medically Eligible for Transplantation in the Randomized Phase 3 LYM-3002 Study (NCT00722137). Blood, 2014, 124, 3064-3064.	1.4	5
424	Health-Related Quality of Life and Patient-Reported Outcomes in Patients Receiving Ofatumumab in Combination with Fludarabine and Cyclophosphamide (FC) Versus FC Alone in the Complement 2 Trial. Blood, 2015, 126, 5288-5288.	1.4	5
425	Phase 3 zanubrutinib (BGB-3111) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).. Journal of Clinical Oncology, 2018, 36, TPS7581-TPS7581.	1.6	5
426	Type of serum influences the rituximab dependent cytotoxicity and apoptosis of chronic lymphocytic leukemia cells in vitro. Postepy Higieny I Medycyny Doswiadczalnej, 2012, 66, 730-738.	0.1	5
427	Szczepienia ochronne u dorosłych chorych na nowotwory hematologiczne oraz u chorych z asplenią... – zalecenia PTHi i sekcji do spraw zakażeń, PALG. Acta Haematologica Polonica, 2018, 49, 93-101.	0.3	5
428	Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study. Blood, 2020, 136, 38-39.	1.4	5
429	The influence of recombinant human tumor necrosis factor $\beta$ and its muteins used alone or in combination with 2-chlorodeoxyadenosine on normal and leukemic hematopoiesis in vitro. Leukemia Research, 1997, 21, 857-865.	0.8	4
430	A novel B-CLL specific nuclear protein (p44/46). Leukemia Research, 1999, 23, 833-841.	0.8	4
431	Lack of effect of repeated suberythemat ultraviolet-B exposures on human blood dendritic subtypes. Photodermatology Photoimmunology and Photomedicine, 2005, 21, 249-253.	1.5	4
432	Rituximab Plus Purine Nucleoside Analogs in the Treatment of Indolent Lymphoid Malignancies. American Journal of Cancer, 2005, 4, 279-292.	0.4	4

#	ARTICLE	IF	CITATIONS
433	APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2010, 2, e2010011.	1.3	4
434	The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature. <i>Leukemia and Lymphoma</i> , 2012, 53, 820-829.	1.3	4
435	Circulating endothelial cell kinetics and their potential predictive value during mobilization procedure. <i>Journal of Clinical Apheresis</i> , 2013, 28, 341-348.	1.3	4
436	In vivo and ex vivo responses of CLL cells to purine analogs combined with alkylating agent. <i>Pharmacological Reports</i> , 2013, 65, 460-475.	3.3	4
437	The efficacy of sapacitabine in treating patients with acute myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1835-1839.	1.8	4
438	Venetoclax Improves Quality of Life for Patients with Elapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 4858-4858.	1.4	4
439	Cladribine Alone or in Combination with Cyclophosphamide or Cyclophosphamide and Mitoxantrone as First Line Treatment in Chronic Lymphocytic Leukemia: An Early Report of Prospective Randomized Study.. <i>Blood</i> , 2004, 104, 337-337.	1.4	4
440	Incidence of Genomic Aberrations and Associated Efficacy from a Phase III Study Comparing Alemtuzumab (CAMPATH <sup>®</sup> , MABCAMPATH <sup>®</sup> ) vs Chlorambucil as First Line Therapy for B-Cell Chronic Lymphocytic Leukemia (BCLL).. <i>Blood</i> , 2006, 108, 2092-2092.	1.4	4
441	Erythropoiesis-Stimulating Agents Do Not Adversely Affect Long-Term Outcomes Nor Increase the Risk of Thromboembolic Events in Multiple Myeloma Patients Treated in the Phase III VISTA Trial.. <i>Blood</i> , 2008, 112, 1741-1741.	1.4	4
442	Phase 2 Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR™ Protein, in Combination with Bendamustine Vs Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL) - Updated Results. <i>Blood</i> , 2014, 124, 5642-5642.	1.4	4
443	Updated results of a phase III randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7515-7515.	1.6	4
444	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytowych na rok 2018/2019. <i>Acta Haematologica Polonica</i> , 2018, 49, 157-206.	0.3	4
445	Safety of the Anti-CD19 antibody Tafasitamab in Long Term Responders from A Phase II Trial for Relapsed Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 270-275.	0.4	4
446	Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE). <i>Blood</i> , 2020, 136, 25-26.	1.4	4
447	New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia. <i>Current Treatment Options in Oncology</i> , 2022, , 1.	3.0	4
448	Prognostic value of thymidine kinase activity in patients with chronic lymphocytic leukemia. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2016, 70, 1321-1330.	0.1	4
449	Acute Lymphoblastic Leukemia in Adult First Manifested as Severe Aplastic Anemiaâ€”Role of Molecular Analysis in Correct Diagnosis. <i>Leukemia and Lymphoma</i> , 2002, 43, 1147-1152.	1.3	3
450	Treatment of chronic lymphoid leukemias with monoclonal antibodies: current place and perspectives. <i>Drug Development Research</i> , 2008, 69, 373-387.	2.9	3

#	ARTICLE	IF	CITATIONS
451	Novel Systemic Drugs for Cutaneous T-Cell Lymphoma. Recent Patents on Anti-Cancer Drug Discovery, 2011, 6, 70-93.	1.6	3
452	Immune thrombocytopenia in patients with chronic lymphocytic leukemia treated with cladribine-based regimens or chlorambucil – follow-up of PALG/CLL randomized trials. European Journal of Haematology, 2013, 91, 1-9.	2.2	3
453	Inhibitors of B-Cell Receptor Signaling for the Treatment of Chronic Lymphocytic Leukemia. Journal of Leukemia (Los Angeles, Calif), 2013, 01, .	0.1	3
454	Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej, białaczki limfocytowej w 2014 r. – raport Grupy Roboczej PTHiT oraz PALG – CLL. Acta Haematologica Polonica, 2014, 45, 221-239.	0.3	3
455	The kinetics of hematopoietic niche cytokines and their influence on mobilization efficacy and timing in patients with hematological malignancies. Journal of Clinical Apheresis, 2015, 30, 247-251.	1.3	3
456	The safety profile of monoclonal antibodies for chronic lymphocytic leukemia. Expert Opinion on Drug Safety, 2017, 16, 1-17.	2.4	3
457	Clinical management of mantle cell lymphoma in the elderly. Expert Opinion on Pharmacotherapy, 2019, 20, 1893-1905.	1.8	3
458	Long-Term Follow-Up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S316.	0.4	3
459	Cereblon ( <i>CRBN</i> ) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium. Leukemia and Lymphoma, 2020, 61, 699-706.	1.3	3
460	The safety of available chemo-free treatments for mantle cell lymphoma. Expert Opinion on Drug Safety, 2020, 19, 1377-1393.	2.4	3
461	IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen. Scientific Reports, 2021, 11, 10017.	3.3	3
462	Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison. Blood, 2018, 132, 5565-5565.	1.4	3
463	Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and del(17p): Arm D of the SEQUOIA (BGB-3111-304) Trial. Blood, 2020, 136, 24-25.	1.4	3
464	Randomized Comparison of Weekly Administration and Daily Courses of Cladribine in Patients with Hairy Cell Leukemia - Updated Results.. Blood, 2004, 104, 3478-3478.	1.4	3
465	Addition of Cladribine to the Standard Daunorubicine - Cytarabine (DA 3+7) Remission Induction Protocol (DAC) Contrary to Adjunct of Fludarabine (DAF) Improves the Overall Survival in Untreated Adults with Acute Myeloid Leukemia Aged up to 60 Y: A Multicenter, Randomized, Phase III PALG AML 1/2004 DAF/DAC/DA Study in 673 Patients. Blood, 2008, 112, 133-133.	1.4	3
466	Overall Survival Advantage and Acceptable Safety Profile with Fludarabine In Combination with Alemtuzumab (FluCam) In Previously Treated Patients with Advanced Stage Chronic Lymphocytic Leukemia. Blood, 2010, 116, 919-919.	1.4	3
467	Polymorphisms of Mir-34b/c, Mir-146a and Mir-196a-2 and Predisposition to Chronic Lymphocytic Leukemia and Monoclonal B-Cell Lymphocytosis. Blood, 2011, 118, 4585-4585.	1.4	3
468	Final Results From a Phase II Trial with the First in Class Recombinant Polyclonal Antibody Product Rozrolimupab in Primary Immune Thrombocytopenia. Blood, 2011, 118, 527-527.	1.4	3

#	ARTICLE	IF	CITATIONS
469	Real-Life Comparison Of Severe Vascular Events and Other Non-Hematological Complications In CML Patients Treated With Second Line Nilotinib Or Dasatinib. <i>Blood</i> , 2013, 122, 1491-1491.	1.4	3
470	Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2015, 33, 7012-7012.	1.6	3
471	A large single-institution retrospective analysis of aggressive B-cell lymphomas according to the 2016/2017 WHO classification. <i>Advances in Clinical and Experimental Medicine</i> , 2019, 28, 1359-1365.	1.4	3
472	Cytotoxic and apoptosis-inducing effects of bendamustine used alone and in combination with rituximab on chronic lymphocytic leukemia cells in vitro. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2014, 68, 1433-1443.	0.1	3
473	Expression of Smad Proteins as a Potential Prognostic Factor in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 1957-1957.	1.4	3
474	The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12070.	4.1	3
475	Angiopoietins in haematopoietic stem cell mobilisation in patients with haematological malignancies. <i>Blood Transfusion</i> , 2015, 13, 102-8.	0.4	3
476	Determination of the in vivo effects of cladribine alone and its combination with cyclophosphamide or cyclophosphamide and mitoxantrone on Bax and Bcl-2 protein expression in B-CLL cells. <i>Oncology Reports</i> , 2004, 11, 699-705.	2.6	3
477	Leukemia cutis in accelerated chronic lymphocytic leukemia: successful treatment with venetoclax and rituximab. <i>Annals of Hematology</i> , 2022, 101, 1387-1392.	1.8	3
478	Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib. <i>Journal of Clinical Medicine</i> , 2022, 11, 112.	2.4	3
479	A comparison of the Antileukaemic Effects of Recombinant Human Tumour Necrosis Factor- $\hat{\pm}$ and its Muteins on Leukaemia L1210 and Leukaemia P388 in Mice. <i>Mediators of Inflammation</i> , 1994, 3, 411-414.	3.0	2
480	Impact of granulocyte colony stimulating factor administered during induction and consolidation of adults with acute lymphoblastic leukemia on survival: long-term follow-up of the Polish adult leukemia group 4-96 study. <i>Leukemia and Lymphoma</i> , 2009, 50, 1050-1053.	1.3	2
481	The evaluation and optimal use of rituximab in lymphoid malignancies. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2012, , 1.	2.7	2
482	PrzeciwciaÅ,a monoklonalne w leczeniu przewlekÅ,ej biaÅ,aczki limfocytowej. <i>Acta Haematologica Polonica</i> , 2012, 43, 99-106.	0.3	2
483	PrzewlekÅ,a biaÅ,aczka limfocytowa u ludzi starszych. <i>Acta Haematologica Polonica</i> , 2013, 44, 93-98.	0.3	2
484	Novel therapies under investigation for mantle cell lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 375-380.	4.1	2
485	Concurrent treatment with two B-cell receptor pathway inhibitors. <i>Lancet Haematology,the</i> , 2019, 6, e8-e9.	4.6	2
486	A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial. <i>Leukemia and Lymphoma</i> , 2020, 61, 1748-1751.	1.3	2

#	ARTICLE	IF	CITATIONS
487	Multifocal osteolytic lesions in hairy cell leukemia— the importance of PET/CT in diagnosis and assessment. <i>Annals of Hematology</i> , 2021, 100, 1641-1645.	1.8	2
488	Cutaneous leukocytoclastic vasculitis at diagnosis of hairy cell leukemia successfully treated with vemurafenib and rituximab. <i>Leukemia Research</i> , 2021, 104, 106571.	0.8	2
489	The Influence of 2-Chlorodeoxyadenosine (2-CdA) Alone and in Combination with Cyclophosphamide or Methotrexate on Normal and Leukemic Hematopoiesis. <i>Advances in Experimental Medicine and Biology</i> , 1995, 370, 129-130.	1.6	2
490	Long Term Nomacopan Administration Results in Complete Transfusion Independence in Previously Transfusion-Dependent PNH Patients. <i>Blood</i> , 2019, 134, 4797-4797.	1.4	2
491	Outcome of Patients with Hodgkin Lymphoma Treated with Brentuximab Vedotin for Relapse after Autologous Stem Cell Transplant: A Retrospective Analysis of the LWP-EBMT. <i>Blood</i> , 2019, 134, 4018-4018.	1.4	2
492	Rapamycin, Inhibitor of Mtor Kinase, Sensitizes Leukemia Cells to Fludarabine-Induced Apoptosis, but Protects Survival of Normal Lymphocytes.. <i>Blood</i> , 2004, 104, 4497-4497.	1.4	2
493	Bortezomib (Btz) Dose Intensity Is the Strongest Predictor for Overall Survival (OS) in Mantle Cell Lymphoma (MCL) Patients (Pts) Not Considered for Transplantation, Receiving Frontline Btz Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Therapy in the Phase 3 LYM-3002 Study. <i>Blood</i> , 2014, 124, 4412-4412.	1.4	2
494	Responses to Romidepsin in Patients with Cutaneous T-Cell Lymphoma (CTCL) and Prior Treatment with Systemic Chemotherapy: Subanalysis from the Pivotal Phase 2 Study. <i>Blood</i> , 2014, 124, 4451-4451.	1.4	2
495	A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS7127-TPS7127.	1.6	2
496	Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL): Final analysis of the phase 3 COMPLEMENT 1 trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7528-7528.	1.6	2
497	Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7513-7513.	1.6	2
498	Clinically Significant Responses Achieved with Romidepsin in 37 Patient with Cutaneous T-Cell Lymphoma (CTCL) with Blood Involvement.. <i>Blood</i> , 2009, 114, 2683-2683.	1.4	2
499	The influence of 2- chlorodeoxyadenosine in combination with tumour necrosis factor- $\beta$ or its mutein on murine leukaemias L1210 and P388. <i>Mediators of Inflammation</i> , 1995, 4, 205-208.	3.0	1
500	Atypical Chronic Myelogenous Leukemia Following Immunosuppressive Therapy for Severe Aplastic Anemia. <i>Leukemia and Lymphoma</i> , 1999, 35, 193-199.	1.3	1
501	Amifostine and 2-CdA: a novel purging strategy in CML autografting?. <i>European Journal of Haematology</i> , 2000, 64, 347-349.	2.2	1
502	Altered Expression of Nuclear Non-Histone Protein (P44/46) in Different Stages of B-Chronic Lymphocytic Leukemia. <i>Leukemia and Lymphoma</i> , 2001, 41, 635-642.	1.3	1
503	Chlorambucil for the treatment of patients with chronic lymphocytic leukaemia, or small lymphocytic lymphoma. <i>The Cochrane Library</i> , 2011, , .	2.8	1
504	CD38 gene polymorphisms and genetic predisposition to multiple myeloma. <i>Acta Haematologica Polonica</i> , 2013, 44, 58-62.	0.3	1

#	ARTICLE	IF	CITATIONS
505	Novel target to kill CLL. <i>Blood</i> , 2015, 125, 211-212.	1.4	1
506	Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej białaczki limfocytowej w 2016 r. – Raport Grupy Roboczej PTHiT i PALG-CLL. <i>Acta Haematologica Polonica</i> , 2016, 47, 169-183.	0.3	1
507	Innovation in non-Hodgkin lymphoma drug discovery: what needs to be done?. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 1033-1045.	5.0	1
508	Will combination therapy with targeted drugs be better for achieving remission in chronic lymphocytic leukemia?. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1675-1678.	1.8	1
509	Analiza skuteczności ibrutinibu w podgrupie chorych na przewlekłą białaczkę limfocytową z delecją 17p: badanie obserwacyjne Polskiej Grupy ds. Leczenia Białaczek u Dorosłych (PALG). <i>Acta Haematologica Polonica</i> , 2017, 48, 330-337.	0.3	1
510	Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S317.	0.4	1
511	Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG). <i>Leukemia and Lymphoma</i> , 2020, 61, 588-603.	1.3	1
512	The role of NF- $\kappa$ B and Smac/DIABLO proteins in the treatment response and survival of acute myeloid leukemia patients. <i>Archives of Medical Science</i> , 2021, 17, 700-707.	0.9	1
513	Pharmacogenetic Analysis of Polymorphisms in Pharmacological Pathway of Vincristine, Doxorubicine and Dexamethasone (VAD Regimen) To Predict Response in Patients with Multiple Myeloma.. <i>Blood</i> , 2005, 106, 104-104.	1.4	1
514	Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib ± Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma.. <i>Blood</i> , 2007, 110, 2735-2735.	1.4	1
515	Randomized Comparison of Cladribine Plus Cyclophosphamide with Fludarabine Plus Cyclophosphamide in Untreated Patients with Chronic Lymphocytic Leukemia: Report of the Polish Adult Leukemia Group (PALG-CLL3).. <i>Blood</i> , 2008, 112, 2103-2103.	1.4	1
516	Ex Vivo Cytotoxic Activity of Endoribonucleases, Onconase (ranpirnase) and R-Amphinase, against Acute Myeloblastic Leukemia Cells. <i>Blood</i> , 2008, 112, 4010-4010.	1.4	1
517	Quality-Adjusted Survival (Q-TWiST) Analysis of Patients with Relapsed or Refractory Chronic Lymphocytic Leukaemia Treated with Rituximab Plus Fludarabine and Cyclophosphamide (R-FC) Versus FC Alone.. <i>Blood</i> , 2009, 114, 1368-1368.	1.4	1
518	FC-Gamma Receptor (FCGR) 2A and 3A Polymorphisms Do Not Influence the Outcome of Relapsed or Refractory CLL Patients Treated with Rituximab, Fludarabine, and Cyclophosphamide (R-FC) or Fludarabine, and Cyclophosphamide (FC) Alone.. <i>Blood</i> , 2009, 114, 2338-2338.	1.4	1
519	Long-Term Health Outcomes and Costs Associated with the Use of Rituximab in Combination with fludarabine and Cyclophosphamide (R-FC) in the Treatment of relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) in Poland.. <i>Blood</i> , 2009, 114, 4528-4528.	1.4	1
520	The Prognostic Role of Jagged-1 Protein Expression In Acute Myeloid Leukemia Patients. <i>Blood</i> , 2010, 116, 2726-2726.	1.4	1
521	A Randomized, Multicenter Study (PALG CLL4/ ML 21283) Of Maintenance Treatment With Rituximab Versus Observation After Induction Treatment With Rituximab, Cladribine, and Cyclophosphamide (RCC) Regimen In Patients With Progressive Chronic Lymphocytic Leukemia: Interim Analysis. <i>Blood</i> , 2013, 122, 1640-1640.	1.4	1
522	Cladribine, Cytarabine and Mitoxantrone As Treatment Intensification for Patients with Acute Myeloid Leukemia with the Excess of Bone Marrow Blasts on Day 14 of the First Induction. Prospective, Multicenter Study by the Polish Adult Leukemia Group (PALG). <i>Blood</i> , 2016, 128, 213-213.	1.4	1

#	ARTICLE	IF	CITATIONS
523	Slower Engraftment in Patients with High Expression of miRNA-15a, miRNA-16, miRNA-126, miRNA-146a, miRNA-223 Prior to Autologous Stem Cell Transplantation and at Early Time after Transplantation. <i>Blood</i> , 2016, 128, 5717-5717.	1.4	1
524	Phase IIa study of single-agent MOR208 in patients with relapsed or refractory B-cell non-Hodgkinâ€™s lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8500-8500.	1.6	1
525	Patterns of hepatitis B reactivation and liver test abnormalities in patients with chronic lymphocytic leukemia (CLL) treated with idelalisib plus an anti-CD20 antibody.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7533-7533.	1.6	1
526	Moxetumomab pasudotox in heavily pretreated patients with relapsed/refractory hairy cell leukemia: Results of a pivotal international study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7004-7004.	1.6	1
527	Ofatumumab for the treatment of chronic lymphocytic leukemia. <i>Therapy: Open Access in Clinical Medicine</i> , 2009, 6, 577-587.	0.2	1
528	Addition of Cladribine to the Standard AML Treatment Improves Long-Term Outcome in High Tumor Burden and Older Than 40 Years Acute Myeloid Leukemia Patients. Five-Year Follow-Up of the Polish Adult Leukemia Group (PALG 1999 DAC vs. DA Study).. <i>Blood</i> , 2004, 104, 1795-1795.	1.4	1
529	Cytotoxic Effect of Proteasome Inhibitor Bortezomib in Combination with Purine Nucleoside Analogues on Chronic Lymphocytic Leukemia Cells in Vitro.. <i>Blood</i> , 2004, 104, 4822-4822.	1.4	1
530	Randomized Comparison of Cladribine Plus Cyclophosphamide with Fludarabine Plus Cyclophosphamide in Progressive Chronic Lymphocytic Leukemia: An Updated Report of Prospective PALG-CLL3 Study.. <i>Blood</i> , 2006, 108, 2826-2826.	1.4	1
531	Effect of Disease Stage and Time Since Diagnosis on Time to Progression for Pegylated Liposomal Doxorubicin + Bortezomib vs Bortezomib Alone in Relapsed or Refractory Multiple Myeloma.. <i>Blood</i> , 2007, 110, 2740-2740.	1.4	1
532	CD38 Gene Polymorphisms Contribute to Genetic Predisposition to B-Cell Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2007, 110, 491-491.	1.4	1
533	Efficacy and Safety of a New Intravenous Immunoglobulin Product in Patients with Chronic Immune Thrombocytopenic Purpura.. <i>Blood</i> , 2007, 110, 1307-1307.	1.4	1
534	Activity of Anti-Tumor Endoribonucleases, Onconase (ranpirnase) and R-Amphinase in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2008, 112, 4205-4205.	1.4	1
535	Cladribine in Combination with Standard Daunorubicine and Cytarabine (DAC) as a Remission Induction Treatment Improves the Overall Survival in Untreated Adults with AML Aged < 60 y Contrary to Combination Including Fludarabine (DAF): A Multicenter, Randomized, Phase III PALG AML 1/2004 DAC/DAF/DA Study in 673 Patients-A Final Update.. <i>Blood</i> , 2009, 114, 2055-2055.	1.4	1
536	Changes In Apoptotic Gene Expression Profile In CLL Patients Treated with Cladribine, Cyclophosphamide and Rituximab (CCR). <i>Blood</i> , 2010, 116, 2469-2469.	1.4	1
537	Kinetics and Apoptotic Profile of Circulating Endothelial Cells In Patients Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 2961-2961.	1.4	1
538	Polymorphisms Of Human Leukocyte Antigen-G Gene and Clinical Outcome Of Patients With Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 4151-4151.	1.4	1
539	Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin with Bortezomib Alone in Subjects with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 3448-3448.	1.4	1
540	Blockage of Wnt/B-Catenin Signaling By Nanoparticles Reduces Survival and Proliferation of CLL Cells in Vitro. <i>Blood</i> , 2015, 126, 3699-3699.	1.4	1

#	ARTICLE	IF	CITATIONS
541	Nonconventional Gene Expression within the NF- $\kappa$ B Signaling Pathway Induced By Poly(propylene)Imine Glycodendrimers in Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2016, 128, 5595-5595.	1.4	1
542	Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia. <i>Hematologic Malignancies</i> , 2019, , 107-119.	0.2	1
543	Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Na $\bar{A}$ ve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study. <i>Blood</i> , 2019, 134, 4235-4235.	1.4	1
544	Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens. <i>Journal of Clinical Medicine</i> , 2021, 10, 5028.	2.4	1
545	OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM) - Renal Impairment (RI) Analysis. <i>Blood</i> , 2021, 138, 4777-4777.	1.4	1
546	An Open Label, Phase 2 Study to Assess the Efficacy and Safety of Tenisib (RP6530), a PI3K $\hat{\gamma}$ / $\beta$ and SIK3 Inhibitor, in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 25-25.	1.4	1
547	The Prosid Study: Evaluating Efficacy and Safety of Intravenous Immunoglobulin (IVIG) 10% in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia- Study Design. <i>Blood</i> , 2020, 136, 20-21.	1.4	1
548	Dexamethasone does not enhance antileukemic activity of cladribine in mice with leukemias L1210 and P388. <i>Neoplasma</i> , 2000, 47, 168-71.	1.6	1
549	The EHA Research Roadmap: Malignant Lymphoid Diseases. <i>HemaSphere</i> , 2022, 6, e726.	2.7	1
550	Emerging drugs for rarer chronic lymphoid leukemias. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 95-118.	2.4	0
551	New Therapies for Patients with Chronic Lymphocytic Leukemia. <i>Current Cancer Therapy Reviews</i> , 2008, 4, 235-242.	0.3	0
552	A Review of the Management of Chronic Myeloid Leukemia with Dasatinib. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S1167.	0.1	0
553	Dasatinib in the Treatment of Chronic Myeloid Leukemia. <i>Current Signal Transduction Therapy</i> , 2011, 6, 99-105.	0.5	0
554	Editorial [Hot Topic: Novel and Emerging Drugs for Leukemias (Guest Editor: Tadeusz Robak)]. <i>Current Cancer Drug Targets</i> , 2012, 12, 453-457.	1.6	0
555	Changes in the apoptotic gene expression profile in CLL patients treated with rituximab combined with cladribine and cyclophosphamide-preliminary results. <i>Leukemia Research</i> , 2012, 36, 1134-1140.	0.8	0
556	Polymorphisms of the glucocorticoid receptor gene: impact on clinical outcome of multiple myeloma. <i>Comparative Clinical Pathology</i> , 2013, 22, 157-163.	0.7	0
557	Przewlekła, a białaczka limfocytowa wysokiego ryzyka. <i>Acta Haematologica Polonica</i> , 2015, 46, 68-74.	0.3	0
558	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskracji plazmocytowych na rok 2015. <i>Acta Haematologica Polonica</i> , 2015, 46, 159-211.	0.3	0



#	ARTICLE	IF	CITATIONS
559	Antibody-Drug Conjugates and Immunotoxins for the Treatment of Hematologic Neoplasms. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 89-128.	0.1	0
560	Iksazomib u chorych z nawrotowym lub opornym na leczenie szpiczakiem plazmocytowym. Acta Haematologica Polonica, 2017, 48, 160-164.	0.3	0
561	Five-Year Follow-Up After Ibrutinib Therapy for First-Line Treatment of Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S274.	0.4	0
562	Chronic lymphocytic leukemia. HemaSphere, 2019, 3, 36.	2.7	0
563	Bendamustine alone or with rituximab modifies expression of apoptosis-regulating genes and proteins of CLL cells, depending on IGVH mutational status. Leukemia and Lymphoma, 2019, 60, 1409-1419.	1.3	0
564	Der Stand der Therapie bei der refraktären/rezidivierenden chronischen lymphatischen Leukämie: Neuartige Wirkstoffe im Fokus. Karger Kompass Onkologie, 2021, 8, 59-69.	0.0	0
565	Hairy Cell Leukemia. Hematologic Malignancies, 2021, , 179-194.	0.2	0
566	The Effect of Subsequent Therapies in the Patients with Chronic Lymphocytic Leukemia Previously Treated with Cladribine and Prednisone or Chlorambucil and Prednisone in Randomized Studies.. Blood, 2004, 104, 4819-4819.	1.4	0
567	Analysis of Common Single Nucleotide Polymorphisms in MDR1 Gene in Patients with Multiple Myeloma.. Blood, 2004, 104, 4371-4371.	1.4	0
568	Addition of Purine Analogues to Induction/Consolidation Regimen Does Not Impair Peripheral Blood Stem Cell Mobilization and Bone Marrow Harvest for Autotransplantation in Acute Myeloid Leukemia.. Blood, 2004, 104, 5198-5198.	1.4	0
569	The VH3-21 Gene Status Correlates with Elevated $\beta_2$ -Microglobulin Serum Levels and Shorter Overall Survival of Patients with Chronic Lymphocytic Leukemia.. Blood, 2005, 106, 4988-4988.	1.4	0
570	Randomized Comparison of Cladribine Containing Regimens and COP in Previously Untreated Patients with Small Lymphocytic, Marginal Zone and Follicular Lymphoma.. Blood, 2005, 106, 4739-4739.	1.4	0
571	Anti-CD20 and Anti-CD52 Monoclonal Antibodies Enhance Cytotoxicity of Bortezomib Against Chronic Lymphocytic Leukemia Cells.. Blood, 2005, 106, 2972-2972.	1.4	0
572	Inhibition of mTOR Kinase Pathway Selectively Sensitizes Acute Myeloid Leukemia Cells to Cytarabine-Induced Apoptosis.. Blood, 2005, 106, 2474-2474.	1.4	0
573	Prospective, Randomized, Multicenter Phase III, Polish Adult Leukemia Group (PALG) Study Comparing DAF (DNR+AraC+Fludarabine), DAC (DNR+AraC+Cladribine), and Standard DA Regimen in Induction of Untreated Acute Myeloid Leukemia Patients - First Report.. Blood, 2005, 106, 4616-4616.	1.4	0
574	Cytotoxic Effect of R-Etodolac (SDX-101) in Combination with Purine Analogues or Monoclonal Antibodies on Ex-Vivo B-Cell Chronic Lymphocytic Leukemia Cells.. Blood, 2005, 106, 2122-2122.	1.4	0
575	Improved Survival in Acute Myeloid Leukaemia Patients Aged over 40 Given Cladribine in Combination with Standard Remission Induction (DA 3+7) and Consolidation Treatment (HD AraC). Seven Year Follow-Up of Prospective, Cooperative PALG Study.. Blood, 2006, 108, 2003-2003.	1.4	0
576	Deficiency of Blood Dendritic Cells in Patients with Multiple Myeloma: Possible Significance for Prediction of Response to First Line Treatment.. Blood, 2006, 108, 5032-5032.	1.4	0

#	ARTICLE	IF	CITATIONS
577	Pharmacogenetics of Response to Glucocorticosteroids in Adults with Acute Lymphoblastic Leukemia.. Blood, 2006, 108, 2609-2609.	1.4	0
578	The Reduction of Leukemic Blasts in Bone Marrow Aspirate on Day 6 of Remission Induction Treatment Is Predictive for Complete Remission Rate and Survival in Adult Acute Myeloid Leukemia; the Results of Multicenter, Prospective Polish Adult Leukemia Group Trial.. Blood, 2007, 110, 4375-4375.	1.4	0
579	Influence of High Expression of p73 and p53 Proteins on Clinical Outcome in Acute Myeloid Leukemia Patients.. Blood, 2007, 110, 4306-4306.	1.4	0
580	Circulating Endothelial Cells as Noninvasive Marker of Angiogenesis in Patients with Chronic Lymphocytic Leukemia.. Blood, 2007, 110, 1124-1124.	1.4	0
581	Polymorphisms in CD31/PECAM-1 and CD38 Genes Are Associated with Susceptibility to Multiple Myeloma. Blood, 2008, 112, 5113-5113.	1.4	0
582	Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Cladribine. Blood, 2008, 112, 4179-4179.	1.4	0
583	Palifermin Does Not Influence the Incidence and Severity of GvHD Nor Long-Term Survival of Patients with Hematological Diseases Undergoing HSCT. Blood, 2008, 112, 4301-4301.	1.4	0
584	Expression and Prognostic Significance of the Inhibitor of Apoptosis Protein (IAPs) Family and Its Antagonists in Chronic Lymphocytic Leukemia. Blood, 2008, 112, 360-360.	1.4	0
585	High Serum Level of Placental Growth Factor (PlGF) Predicts Adverse Overall Survival in Patients with Acute Myeloid Leukemia Treated with Standard Chemotherapy. Blood, 2008, 112, 3972-3972.	1.4	0
586	Impact of Interleukin-10 Gene Promoter Polymorphisms on Clinical Course of Chronic Lymphocytic Leukemia. Blood, 2008, 112, 4168-4168.	1.4	0
587	Osteopontin - A New Angiogenic Factor Which Correlates with Circulating Endothelial Cells in Acute Myeloid Leukemia.. Blood, 2009, 114, 1004-1004.	1.4	0
588	The Prognostic Role of Smac/DIABLO Protein Expression in Acute Myeloid Leukemia.. Blood, 2009, 114, 2626-2626.	1.4	0
589	The TNF $\gamma$ 308G>A Polymorphism Predicts Outcome of Patients with B-Cell Chronic Lymphocytic Leukemia In Relation to the IgVH Mutation Status. Blood, 2010, 116, 2421-2421.	1.4	0
590	Improved Outcome of Adult Acute Lymphoblastic Leukemia Treated with Individualized Protocol Adjusted to the Status of Minimal Residual Disease and Age. Interim Analysis of PALG ALL 5 <sup>th</sup> 2007 Study. Blood, 2010, 116, 2138-2138.	1.4	0
591	The Role of Inhibitor of Apoptosis Proteins Family Expression In Acute Myeloid Leukemia Patients. Blood, 2010, 116, 2728-2728.	1.4	0
592	Clinical Relevance of Vascular Endothelial Growth Factor Type A (VEGFA) and VEGF Receptor Type 2 (VEGFR2) Gene Polymorphism In Chronic Lymphocytic Leukemia. Blood, 2010, 116, 4467-4467.	1.4	0
593	Antitumor Activity of Amphibian Ribonucleases, Onconase and R-Amhinase, on Tumor Cells From B-Cell Lymphoproliferative Disorders. Blood, 2010, 116, 2842-2842.	1.4	0
594	Treatment of Elderly Patients with Acute Myeloid Leukemia Adjusted to Age, Performance Status, Organ Function and the Presence of Co-Morbidities. Final Results of the Polish Adult Leukemia Group (PALG) 1/2005 Study.. Blood, 2010, 116, 1067-1067.	1.4	0

#	ARTICLE	IF	CITATIONS
595	Assessment of Minimal Residual Disease (MRD) In Relapsed CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab (REACH). Blood, 2010, 116, 1390-1390.	1.4	0
596	Older and New Formulations of Cladribine: Pharmacology and Clinical Efficacy in Hematological Malignancies. , 2011, , 497-524.		0
597	Novel Purine Nucleoside Analogues for Hematological Malignancies. , 2011, , 219-240.		0
598	Is Type of Monosomy (Total or Partial) Crucial for Prognostic Value of Monosomal Karyotype in AML Patients? â€œ Preliminary Results of Retrospective Polish Adult Leukemia Group (PALG) Study,. Blood, 2011, 118, 3537-3537.	1.4	0
599	Disruption of TP53 function by Point Mutations and Deletions Is Associated with An Increased Risk of Disease Progression within Previously Treated, Relapsed Chronic Lymphocytic Leukemia Patients. Blood, 2011, 118, 2445-2445.	1.4	0
600	Pro-Apoptotic Effect of An Anti-CD37 Scfv-Fc Fusion Protein, in Combination with the Anti-CD20 Antibody, Ofatumumab, on Tumor Cells From B-Cell Malignancies. Blood, 2011, 118, 1662-1662.	1.4	0
601	Low Expression of MiR-34a in Previously Treated Chronic Lymphocytic Leukemia Patients Is Limited to Patients with a Complete Disruption of TP53 Function and Does Not Correlate with MDM2 SNP309,. Blood, 2011, 118, 3521-3521.	1.4	0
602	Diverse Impact of Notch-1, Jagged-1 and Dll-1 Expression On Response to Treatment and Relapse Free Survival in Acute Myeloid Leukemia.. Blood, 2012, 120, 2520-2520.	1.4	0
603	Daunorubicine, Cytarabine and Cladribine (DAC) Vs Daunorubicine and Cytarabine (DA) Induction Treatment in Elderly Acute Myeloid Leukemia (AML) Patients â€œ Results of the Prospective, Multicenter, Randomized Trial of the Polish Adult Leukemia Group (PALG). Blood, 2012, 120, 3602-3602.	1.4	0
604	New Monoclonal Antibodies for Indolent Non-Hodgkin Lymphoma. , 2013, , 191-212.		0
605	Polymorphism Of CD44 Influences Efficacy Of CD34+Cells Mobilization In Patients With Hematological Malignancies. Blood, 2013, 122, 3270-3270.	1.4	0
606	Purine Analogues Based Induction Regimen Followed By Allo-HSCT Is An Effective Treatment Modality Of Philadelphia Chromosome-Positive Acute Myeloid Leukemia-Retrospective Analysis Of Polish Adult Leukemia Group (PALG). Blood, 2013, 122, 1461-1461.	1.4	0
607	Clinical Relevance Of VEGF-C/VEGF-D/VEGFR-3 Axis In Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 5060-5060.	1.4	0
608	High Expression Of Cereblon (CRBN) Is Associated With Achievement Of Complete Response To Thalidomide Plus Fludarabine Regimen In Chronic Lymphocytic Leukemia. Blood, 2013, 122, 4934-4934.	1.4	0
609	New Therapies for Chronic Lymphocytic Leukemia. Current Cancer Therapy Reviews, 2014, 9, 245-257.	0.3	0
610	Human Leukocyte Antigen-G Polymorphisms Influence Clinical Outcome in Diffuse Large B-Cell Lymphoma. Blood, 2014, 124, 1643-1643.	1.4	0
611	HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma. Blood, 2014, 124, 1642-1642.	1.4	0
612	Cladribine Added to Daunorubicin and Cytarabine Induction Regimen Prolongs Survival of Patients with Complex but Not Monosomal Karyotype Acute Myeloid Leukemia â€œ Retrospective Analysis of Polish Adult Leukemia Group (PALG). Blood, 2014, 124, 2347-2347.	1.4	0

#	ARTICLE	IF	CITATIONS
613	A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Blood</i> , 2014, 124, 3089-3089.	1.4	0
614	Impact of Drug Transporters ABCB1 and ABCG2 and Regulators of Xenobiotic Transport and Metabolism Pxr and CAR Gene Polymorphisms on Clinical Efficacy of Imatinib in Chronic Myeloid Leukemia (CML). <i>Blood</i> , 2014, 124, 5222-5222.	1.4	0
615	The Role of the Slit-Robo Family in Adult Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3816-3816.	1.4	0
616	Subgroup analyses of diffuse large B-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase IIa study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (R-R NHL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7545-7545.	1.6	0
617	A Distributed International Patient Data Registry for Hairy Cell Leukemia. <i>Blood</i> , 2016, 128, 5986-5986.	1.4	0
618	Altered Endothelial Cells Properties and Platelets Activity in Treatment Na <sup>+</sup> -Ve Patients with Multiple Myeloma (MM ) and Non-Hodgkin Lymphoma (nHL): Association with Thromboembolic Complications. <i>Blood</i> , 2016, 128, 5649-5649.	1.4	0
619	Long-Term Evaluation of Efficacy and Safety of Ofatumumab Added to Fludarabine & Cyclophosphamide in Subjects with Relapsed Chronic Lymphocytic Leukemia: Final Analysis of Complement 2 Trial. <i>Blood</i> , 2018, 132, 3151-3151.	1.4	0
620	Wenetoklaks w leczeniu chor <sup>3b</sup> uk <sup>3</sup> adu krwiotw <sup>3</sup> rczego i guz <sup>3</sup> w litych. <i>Acta Haematologica Polonica</i> , 2019, 50, 41-50.	0.3	0
621	The role of neuronal apoptosis inhibitory protein (NAIP) in acute myeloid leukemia patients. <i>Acta Haematologica Polonica</i> , 2019, 50, 74-80.	0.3	0
622	Early Mortality in Patients with Multiple Myeloma Treated with Novel Agents - Analysis from Polish Myeloma Study Group. <i>Blood</i> , 2020, 136, 36-37.	1.4	0
623	A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients $\geq$ 60 Years Old (PALG-AML1/2016). <i>Blood</i> , 2020, 136, 3-4.	1.4	0
624	The influence of venetoclax, used alone or in combination with cladribine (2-CdA), on CLL cells apoptosis in vitro: Preliminary results. <i>Advances in Clinical and Experimental Medicine</i> , 2022, 31, 0-0.	1.4	0